Equaly
Equaly is dedicated to unlocking the therapeutic potential of the innate immune system to develop innovative treatments for cancer, infectious diseases, and autoimmune diseases. Their platform modulates immune responses based on antigen-specific cells, enabling the development of new immunotherapies and biologicals. They focus on creating accessible therapies that aim to cure diseases at their core, rather than just alleviating symptoms, through collaborations and cutting-edge technology.
Industries
Nr. of Employees
small (1-50)
Products
NKT-targeting platform for peptide discovery and protein optimization
A technology platform that identifies NKT-activating motifs in proteins, enables design and testing of short peptide immunotherapeutics, and supports engineering of proteins and viral vectors to reduce immunogenicity.
NKT-targeting platform for peptide discovery and protein optimization
A technology platform that identifies NKT-activating motifs in proteins, enables design and testing of short peptide immunotherapeutics, and supports engineering of proteins and viral vectors to reduce immunogenicity.
Services
Fee-for-service experimental R&D
Provision of expert laboratory support to identify NKT-activating motifs, produce candidate peptides/proteins and perform in vitro NKT activation testing on human samples.
Collaborations and licensing agreements
Collaborative development and licensing models including exclusivity, upfronts, milestones and royalties for co-development or out-licensing of platform-enabled therapeutics.
Co-development and in-house R&D collaborations
Co-development projects combining internal R&D resources with external partners to advance platform-derived candidates or to apply the platform to partner targets.
Fee-for-service experimental R&D
Provision of expert laboratory support to identify NKT-activating motifs, produce candidate peptides/proteins and perform in vitro NKT activation testing on human samples.
Collaborations and licensing agreements
Collaborative development and licensing models including exclusivity, upfronts, milestones and royalties for co-development or out-licensing of platform-enabled therapeutics.
Co-development and in-house R&D collaborations
Co-development projects combining internal R&D resources with external partners to advance platform-derived candidates or to apply the platform to partner targets.
Expertise Areas
- Innate immunology and NKT cell biology
- Peptide immunotherapeutic discovery
- Protein engineering to mitigate immunogenicity
- Preclinical assay development using human immune cells
Key Technologies
- NKT-activating peptide design
- Protein motif prediction and ranking algorithms
- Synthetic peptide synthesis
- Recombinant protein production